1. Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
- Author
-
Awada, Ahmad, Gil, Thierry, Whenham, Nicolas, Van Hamme, Julie, Besse-Hammer, Tatiana, Brendel, Erich, Delesen, Heinz, Joosten, Miranda C, Lathia, Chetan, Loembé, Bienvenu A, Piccart-Gebhart, Martine, Hendlisz, Alain, Awada, Ahmad, Gil, Thierry, Whenham, Nicolas, Van Hamme, Julie, Besse-Hammer, Tatiana, Brendel, Erich, Delesen, Heinz, Joosten, Miranda C, Lathia, Chetan, Loembé, Bienvenu A, Piccart-Gebhart, Martine, and Hendlisz, Alain
- Abstract
Sorafenib (twice daily [bid]) plus capecitabine (2 weeks on schedule/1 week off schedule) safety and pharmacokinetics were investigated in patients with advanced solid tumors (N = 35). Cohort 1 (n = 13) included sorafenib 200 mg bid and capecitabine 1050 mg/m(2) bid; cohort 2 (n = 4), sorafenib 400 mg bid and capecitabine 1050 mg/m(2) bid; cohort 3 (n = 6), sorafenib 200 mg bid and capecitabine 1050 mg/m(2) bid (cycles 1 and 2), then 400 mg bid and capecitabine 1050 mg/m(2) bid (cycle 3 onwards); and cohort 4 (n = 12), sorafenib 400 mg bid and capecitabine 850 mg/m(2) bid. The combination of sorafenib and capecitabine was generally well tolerated. Most frequent drug-related adverse events were hand-foot skin reaction (HFSR, 89%), diarrhea (71%), and fatigue (69%). The HFSR was dose-limiting toxicities in 6 patients. Sorafenib exposure (C(max) and AUC(0-12)) was unaffected by concomitant capecitabine. Concomitant sorafenib moderately increased capecitabine and 5-fluorouracil (metabolite) exposure when the capecitabine dose was 1050 mg/m(2) bid. Simultaneous administration of 400 mg bid sorafenib and 850 mg/m(2) bid capecitabine, however, had only minor effects on the exposure to capecitabine and 5-fluorouracil. Based on the overall toxicity profile and pharmacokinetic parameters, the recommended phase 2 doses were therefore sorafenib 400 mg bid and capecitabine 850 mg/m(2) bid, as scheduled above., Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, FLWIN, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2011